|
GB8607683D0
(en)
|
1986-03-27 |
1986-04-30 |
Ici Plc |
Anti-tumor agents
|
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
|
WO1992020642A1
(en)
|
1991-05-10 |
1992-11-26 |
Rhone-Poulenc Rorer International (Holdings) Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
|
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
EP1514934B1
(en)
|
1992-02-06 |
2008-12-31 |
Novartis Vaccines and Diagnostics, Inc. |
Biosynthetic binding protein for cancer marker
|
|
US6177401B1
(en)
|
1992-11-13 |
2001-01-23 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
|
|
GB9323290D0
(en)
|
1992-12-10 |
1994-01-05 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
|
GB9314884D0
(en)
|
1993-07-19 |
1993-09-01 |
Zeneca Ltd |
Tricyclic derivatives
|
|
GB9314893D0
(en)
|
1993-07-19 |
1993-09-01 |
Zeneca Ltd |
Quinazoline derivatives
|
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
|
GB9510757D0
(en)
|
1994-09-19 |
1995-07-19 |
Wellcome Found |
Therapeuticaly active compounds
|
|
GB9424233D0
(en)
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
|
FI973974A7
(fi)
|
1995-04-20 |
1997-10-16 |
Pfizer |
Aryylisulfonyylihydroksaamihappojohdannaisia MMP- ja TNF-inhibiittorei na
|
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
GB9520822D0
(en)
|
1995-10-11 |
1995-12-13 |
Wellcome Found |
Therapeutically active compounds
|
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
DE69624081T2
(de)
|
1995-12-20 |
2003-06-12 |
Agouron Pharmaceuticals, Inc. |
Matrix-metalloprotease Inhibitoren
|
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
|
JP4464466B2
(ja)
|
1996-03-05 |
2010-05-19 |
アストラゼネカ・ユーケイ・リミテッド |
４―アニリノキナゾリン誘導体
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
CA2260058A1
(en)
|
1996-07-13 |
1998-01-22 |
Kathryn Jane Smith |
Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
|
|
AR007857A1
(es)
|
1996-07-13 |
1999-11-24 |
Glaxo Group Ltd |
Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
|
|
HUP9903014A3
(en)
|
1996-07-18 |
2000-08-28 |
Pfizer |
Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same
|
|
US5866702A
(en)
|
1996-08-02 |
1999-02-02 |
Cv Therapeutics, Incorporation |
Purine inhibitors of cyclin dependent kinase 2
|
|
US6794390B2
(en)
|
1996-08-02 |
2004-09-21 |
Cv Therapeutics, Inc. |
Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
|
|
US6790958B2
(en)
|
1996-08-02 |
2004-09-14 |
Robert T. Lum |
Purine inhibitors of cyclin dependent kinase 2 & IKBA
|
|
IL128189A0
(en)
|
1996-08-23 |
1999-11-30 |
Pfizer |
Arylsulfonylamino hydroxamic acid derivatives
|
|
ES2224277T3
(es)
|
1997-01-06 |
2005-03-01 |
Pfizer Inc. |
Derivados de sulfonas ciclicas.
|
|
PT977733E
(pt)
|
1997-02-03 |
2003-12-31 |
Pfizer Prod Inc |
Derivados de acido arilsulfonilamino-hidroxamico
|
|
JP2000507975A
(ja)
|
1997-02-07 |
2000-06-27 |
ファイザー・インク |
Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
|
|
IL131123A0
(en)
|
1997-02-11 |
2001-01-28 |
Pfizer |
Arylsulfonyl hydroxamic acid derivatives
|
|
CA2289102A1
(en)
|
1997-05-07 |
1998-11-12 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
|
EP0984692A4
(en)
|
1997-05-30 |
2001-02-21 |
Merck & Co Inc |
ANGIOGENESIS INHIBITORS
|
|
AU735127B2
(en)
|
1997-08-07 |
2001-06-28 |
Regents Of The University Of California, The |
Purine inhibitor of protein kinases, G proteins and polymerases
|
|
US6294532B1
(en)
|
1997-08-22 |
2001-09-25 |
Zeneca Limited |
Oxindolylquinazoline derivatives as angiogenesis inhibitors
|
|
WO1999016755A1
(en)
|
1997-09-26 |
1999-04-08 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
|
WO1999024440A1
(en)
|
1997-11-11 |
1999-05-20 |
Pfizer Products Inc. |
Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
|
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
|
TR200003514T2
(tr)
|
1998-05-29 |
2002-05-21 |
Sugen Inc. |
Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
|
|
US6232320B1
(en)
|
1998-06-04 |
2001-05-15 |
Abbott Laboratories |
Cell adhesion-inhibiting antiinflammatory compounds
|
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
|
HUP0301120A2
(hu)
|
2000-06-22 |
2003-08-28 |
Pfizer Products Inc. |
Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények
|
|
US6638926B2
(en)
|
2000-09-15 |
2003-10-28 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
AR042586A1
(es)
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
|
WO2002072549A1
(en)
|
2001-03-12 |
2002-09-19 |
Millennium Pharmaceuticals, Inc. |
Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
|
|
WO2003009852A1
(en)
|
2001-07-24 |
2003-02-06 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US20060009642A1
(en)
|
2001-10-12 |
2006-01-12 |
Irm Llc, A Delaware Limited Liability Company |
Methods for the synthesis of substituted purines
|
|
US7176312B2
(en)
|
2001-10-12 |
2007-02-13 |
The Scripps Research Institute |
Kinase inhibitor scaffolds and methods for their preparation
|
|
US6949644B2
(en)
|
2001-10-12 |
2005-09-27 |
Irm Llc |
Methods for the synthesis of substituted purines
|
|
US7199119B2
(en)
|
2002-10-31 |
2007-04-03 |
Amgen Inc. |
Antiinflammation agents
|
|
WO2005016268A2
(en)
|
2003-08-08 |
2005-02-24 |
Mitochroma Research, Inc. |
Alimentary compositions and methods for metabolic modulation
|
|
US20070161582A1
(en)
|
2003-08-08 |
2007-07-12 |
Dusan Mijikovic |
Pharmaceutical compositions and methods for metabolic modulation
|
|
US20050124637A1
(en)
|
2003-08-15 |
2005-06-09 |
Irm Llc |
Compounds and compositions as inhibitors of receptor tyrosine kinase activity
|
|
US20060029642A1
(en)
|
2004-08-03 |
2006-02-09 |
Dusan Miljkovic |
Methods and compositions for improved chromium complexes
|
|
GB0420719D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
|
FR2876583B1
(fr)
|
2004-10-15 |
2007-04-13 |
Centre Nat Rech Scient Cnrse |
Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
|
|
GB0502573D0
(en)
|
2005-02-08 |
2005-03-16 |
Topotarget As |
Therapeutic compounds
|
|
GB0526246D0
(en)
|
2005-12-22 |
2006-02-01 |
Novartis Ag |
Organic compounds
|
|
US20070253896A1
(en)
|
2006-02-07 |
2007-11-01 |
Conforma Therapeutics Corporation |
7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors
|
|
WO2007105023A1
(en)
|
2006-03-15 |
2007-09-20 |
Csir |
Modulation of phosphoryl transferase activity of glutamine synthetase
|
|
EP2617423A1
(en)
|
2006-10-19 |
2013-07-24 |
Genzyme Corporation |
Purine derivatives for the treatment of cystic diseases
|
|
WO2008057402A2
(en)
|
2006-11-02 |
2008-05-15 |
Cytovia, Inc. |
N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
|
|
WO2008094737A2
(en)
*
|
2007-01-26 |
2008-08-07 |
Irm Llc |
Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
|
|
US8404674B2
(en)
*
|
2007-03-07 |
2013-03-26 |
Boehringer Ingelheim International Gmbh |
Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof
|
|
TW200922569A
(en)
|
2007-08-10 |
2009-06-01 |
Genelabs Tech Inc |
Certain nitrogen containing bicyclic chemical entities for treating viral infections
|
|
CN101827847A
(zh)
|
2007-10-17 |
2010-09-08 |
诺瓦提斯公司 |
用作腺苷a1受体配体的嘌呤衍生物
|
|
US9089572B2
(en)
|
2008-01-17 |
2015-07-28 |
California Institute Of Technology |
Inhibitors of p97
|
|
US20110251172A1
(en)
|
2008-08-13 |
2011-10-13 |
Rivkin Alexey A |
Purine derivatives for treatment of alzheimer's disease
|
|
TW201024298A
(en)
*
|
2008-09-23 |
2010-07-01 |
Palau Pharma Sa |
(R)-3-(N,N-dimethylamino)pyrrolidine derivatives
|
|
PE20100362A1
(es)
|
2008-10-30 |
2010-05-27 |
Irm Llc |
Derivados de purina que expanden las celulas madre hematopoyeticas
|
|
US8426428B2
(en)
*
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
|
WO2010118367A2
(en)
|
2009-04-10 |
2010-10-14 |
Progenics Pharmaceuticals, Inc. |
Antiviral pyrimidines
|
|
US9908884B2
(en)
*
|
2009-05-05 |
2018-03-06 |
Dana-Farber Cancer Institute, Inc. |
EGFR inhibitors and methods of treating disorders
|
|
FR2945747A1
(fr)
*
|
2009-05-25 |
2010-11-26 |
Centre Nat Rech Scient |
Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire
|
|
TW201111385A
(en)
|
2009-08-27 |
2011-04-01 |
Biocryst Pharm Inc |
Heterocyclic compounds as janus kinase inhibitors
|
|
WO2011156889A1
(en)
|
2010-06-14 |
2011-12-22 |
Trt Pharma Inc. |
Novel modulators of nrf2 and uses thereof
|
|
EP2585464A2
(en)
|
2010-06-22 |
2013-05-01 |
University Of Central Florida Research Foundation, Inc. |
Substituted 2-(9h-purin-9-yl) acetic acid analogues as inhibitors of stat3
|
|
EP2627179A4
(en)
*
|
2010-10-14 |
2014-04-02 |
Ariad Pharma Inc |
METHODS OF INHIBITING CELL PROLIFERATION IN EGFR-INDUCED CANCERS
|
|
US9238629B2
(en)
*
|
2010-11-01 |
2016-01-19 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
EP2637502B1
(en)
*
|
2010-11-10 |
2018-01-10 |
Celgene CAR LLC |
Mutant-selective egfr inhibitors and uses thereof
|
|
KR101884010B1
(ko)
*
|
2011-05-04 |
2018-07-31 |
어리어드 파마슈티칼스, 인코포레이티드 |
Egfr-유도된 암의 세포 증식을 억제하는 화합물
|
|
US8762299B1
(en)
|
2011-06-27 |
2014-06-24 |
Google Inc. |
Customized predictive analytical model training
|
|
AU2012311184A1
(en)
*
|
2011-09-22 |
2014-03-06 |
Pfizer Inc. |
Pyrrolopyrimidine and purine derivatives
|
|
CN103159742B
(zh)
|
2011-12-16 |
2015-08-12 |
北京韩美药品有限公司 |
5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
|
|
HK1203927A1
(en)
|
2012-01-13 |
2015-11-06 |
Acea Biosciences, Inc. |
Heterocyclic compounds and uses as anticancer agents
|
|
BR112015023020A2
(pt)
|
2013-03-14 |
2017-07-18 |
Pfizer |
combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas
|
|
US10884952B2
(en)
|
2016-09-30 |
2021-01-05 |
Intel Corporation |
Enforcing memory operand types using protection keys
|